Femasys Inc (FEMY)

Femasys Inc. recorded five insider purchases totaling $134,000 on August 7, 2026. Key executives, including the CEO and CFO, acquired shares shortly before the August 14 earnings report. These acquisitions occurred amidst a 33.7% decline in stock value over the past quarter, reflecting recent market performance trends.
Ticker: FEMY Exchange: NAS


Loading...
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Femasys Inc. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Mifek Jeffrey Gerald Chief Clinical-Medical Affairs Officer
Transaction date
Purchase
Price
232.10
Quantity 14,149 +35.2%
Value US$1,827,196
Sipos Jeremy Alexander Chief Technology Officer Officer
Transaction date
Purchase
Price
183.26
Quantity 76,912 +38.6%
Value US$1,994,596
Canning John Charles Chief Operating Officer Officer
Transaction date
Purchase
Price
307.52
Quantity 39,766 -48.5%
Value US$4,575,315
1.8
Elefant Dov Chief Financial Officer Officer
Transaction date
Purchase
Price
3.20
Quantity 15,625 +inf%
Value US$50,000
Lee-Sepsick Kathy Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.20
Quantity 15,625 +inf%
Value US$50,000
0.9
Dyett John Non-Executive Director Large shareholder
Transaction date
Purchase
Price
9.95
Quantity 1,000 +0.9%
Value US$9,950
0.9
Dyett John Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.00
Quantity 40,000 +400.0%
Value US$520,000
Adams John Q JR Non-Executive Director
Transaction date
Purchase
Price
13.00
Quantity 40,000 +inf%
Value US$520,000
Uzialko Edward R Non-Executive Director
Transaction date
Purchase
Price
13.00
Quantity 100,000 +359.9%
Value US$1,300,000
0.9
Dyett John Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.88
Quantity 10,000 +inf%
Value US$128,800
0.9
Dyett John Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.18
Quantity 2,500 +inf%
Value US$32,950
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-08-11 2026-08-07 B Purchase

Chief Clinical-Medical Affairs

Officer
14,149 +35.2%
232.10
US$1,827,196
14,149 +35.2% 232.10 US$1,827,196
2026-08-11 2026-08-07 B Purchase

Chief Technology Officer

Officer
76,912 +38.6%
183.26
US$1,994,596
76,912 +38.6% 183.26 US$1,994,596
2026-08-11 2026-08-07 B Purchase

Chief Operating Officer

Officer
39,766 -48.5%
307.52
US$4,575,315
39,766 -48.5% 307.52 US$4,575,315
2026-08-11 2026-08-07 B Purchase

Chief Financial Officer

Officer
15,625 +inf%
3.20
US$50,000
15,625 +inf% 3.20 US$50,000
2026-08-11 2026-08-07 B Purchase

Chief Executive Officer

Executive Director
15,625 +inf%
3.20
US$50,000
15,625 +inf% 3.20 US$50,000
2021-06-24 2021-06-23 B Purchase Non-Executive Director Large shareholder
1,000 +0.9%
9.95
US$9,950
1,000 +0.9% 9.95 US$9,950
2021-06-24 2021-06-22 B Purchase Non-Executive Director Large shareholder
40,000 +400.0%
13.00
US$520,000
40,000 +400.0% 13.00 US$520,000
2021-06-24 2021-06-22 B Purchase Non-Executive Director
40,000 +inf%
13.00
US$520,000
40,000 +inf% 13.00 US$520,000
2021-06-24 2021-06-22 B Purchase Non-Executive Director
100,000 +359.9%
13.00
US$1,300,000
100,000 +359.9% 13.00 US$1,300,000
2021-06-24 2021-06-18 B Purchase Non-Executive Director Large shareholder
10,000 +inf%
12.88
US$128,800
10,000 +inf% 12.88 US$128,800
2021-06-24 2021-06-18 B Purchase Non-Executive Director Large shareholder
2,500 +inf%
13.18
US$32,950
2,500 +inf% 13.18 US$32,950